Inventaire - your friends and communities are your best library

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

Author

Igor Puzanov

David I Quinn

Kelly Byrnes-Blake

Published in: Journal for Immunotherapy of Cancer

Date of publication: January 27, 2014

Main subject: renal cell carcinoma, metastatic renal cell carcinoma

Bibliographic databases:

Cites articles 51

Date

Title

Authors

March 1, 1995

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
April 1, 1996

Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding
November 2, 2000

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function
February 2, 2000

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
November 2002

Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses
December 1, 2003

In vivo antitumor activity of interleukin 21 mediated by natural killer cells
July 15, 2004

IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21
February 1, 2004

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
February 1, 2004

IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice
December 1, 2006

The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program
January 19, 2006

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
January 1, 2006

Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma
December 1, 2007

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

, , , , ,
October 5, 2007

IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes
August 1, 2007

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

, ,
June 1, 2007

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma
May 1, 2007

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

, , , ,
February 7, 2007

Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors
January 1, 2007

Sorafenib in advanced clear-cell renal-cell carcinoma

, , , ,
January 11, 2007

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

, ,
August 1, 2007

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer
January 1, 2007

IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes
November 25, 2008

Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment
October 20, 2008

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

, ,
July 22, 2008

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

, ,
May 30, 2008

Angiostatic activity of the antitumor cytokine interleukin-21.

,
February 20, 2008

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma
March 1, 2008

Interleukin 21: combination strategies for cancer therapy
October 1, 2008

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
February 29, 2008

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
March 17, 2008

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
December 1, 2009

The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro

Article -

Welcome to inventaire

The library of your friends and communities

Learn more